CLAIMS

What is claimed is:

~~1. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II"):~~

~~X7-X8-X9-X10-X11-X12-X13-X14-X15-R^2 (II")~~

~~wherein~~

~~X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;~~

~~X8 is Gln, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp;~~

~~X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);~~

~~X10 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy;~~

~~X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;~~

~~X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;~~

~~X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or~~

~~X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;~~

~~X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);~~

~~X15 Leu, (D)Leu, beta-Ala, Cit, or (D)Lys;~~

~~R^2 is OH or NH_2;~~

~~or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;~~

~~and~~

~~wherein the peptide inhibitor or pharmaceutically acceptable salt of solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.~~

~~2. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (I'):~~

~~X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15 (I')~~

~~wherein~~

~~X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);~~

~~X5 is Cit, Glu, Gly, Leu, Ile, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gln, Asp, or Cys; and~~

~~X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, alpha-MeThr, alpha-MeSer, or Val.~~

~~3.~~1. ~~The~~A peptide inhibitor ~~or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor is~~ according to Formula (Z'):

R^1-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-R^2 (Z')

or a pharmaceutically acceptable salt ~~or solvate~~ thereof, wherein

X4 is ~~Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen,~~ Pen~~, or Pen(sulfoxide)~~;

X5 is ~~Cit, Glu, Gly, Leu, Ile, beta-Ala, Ala, Lys,~~ Asn~~, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gln, Asp, or Cys~~; ~~and~~

X6 is Thr~~, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, alpha-MeThr, alpha-MeSer, or Val~~;

X7 is Trp substituted with ~~cyano, halo,~~ alkyl~~, haloalkyl, hydroxy, or alkoxy~~;

X8 is Gln, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp;

X9 is ~~Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen,~~ Pen ~~or Pen(sulfoxide)~~;

X10 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy;

X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, ~~or~~ cyclohexylAla, Lys, or Aib;

X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), ~~or Lys; or X13 is~~ Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;

X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);

X15 is Leu, (D)Leu, beta-Ala, Cit, or (D)Lys;

R^1 is hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-C1-C6alkyl, or a C1-C20 alkanoyl; and

R^2 is OH or NH_2;

wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues ~~or a thioether bond between Abu and Cys~~;

and

wherein the peptide inhibitor or pharmaceutically acceptable salt of solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.

~~4. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises or is any one of the following, or a pharmaceutically acceptable salt or solvate thereof:~~

SEQ ID NO:	Sequence
201	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH_2
202	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
203	Ac-[(D)Arg]-Abu-Q-T-[W(7-Me)]-Q-C-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH_2
204	Ac-Abu-Q-T-[W(7-Me)]-Q-C-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH_2
205	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-G-[bA]-NH_2
206	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[Cit]-[bA]-NH_2
207	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-A-[bA]-NH_2
208	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-L-[bA]-NH_2
209	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Ala]-[bA]-NH_2
214	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-H-[bA]-NH_2
217	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-T-[bA]-NH_2
221	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-S-[bA]-NH_2
222	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Ser]-[bA]-NH_2
226	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[bA]-[bA]-NH_2

SEQ ID NO:	Sequence
227	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH_2
228	Ac-[Pen]-NT-[W(6-Cl)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
229	Ac-[Pen]-NT-[W(4-OMe)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
230	Ac-[Pen]-NT-[W(6-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
231	Ac-[Pen]-NT-[W(4-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
232	Ac-[Pen]-NT-[W(1-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
233	Ac-[Pen]-NT-[W(2,5,7-tritBu)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
234	Ac-[Pen]-NT-[W(7-Me)]-[a-MeLys]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH_2
235	Ac-[Pen]-NT-[W(7-Me)]-[a-MeLeu]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
236	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Aib]-N-[bA]-NH_2
237	Ac-[Pen]-Q-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
238	Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
239	Ac-[Pen]-[Lys(Ac)]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
240	Ac-[Pen]-[Aib]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
241	Ac-[Pen]-NT-[W(7-Me)]-[Aib]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2

SEQ ID NO:	Sequence
242	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
244	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-L-NH_2
245	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
249	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Cit]-NH_2
252	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2
267	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
268	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[bA]-[bA]-NH_2
269	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-L-[bA]-NH_2
270	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[bA]-[bA]-NH_2
271	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-S-[bA]-NH_2
272	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-H-[bA]-NH_2
273	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-[bA]-[bA]-NH_2
279	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Cit]-[bA]-[bA]-NH_2
280	Ac-[Pen]-N-T-[W(1-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[bA]-[bA]-NH_2
281	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Cit]-[bA]-[bA]-NH_2

SEQ ID NO:	Sequence
282	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-N-[bA]-NH_2
283	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[W(1-Me)]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2
284	Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
285	Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
286	Ac-[Pen]-N-T-[W(7-i-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
288	Ac-[Pen]-N-T-[W(7-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
296	Ac-[Pen]-N-T-[W(5-CN)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2
297	Ac-[Pen]-N-T-[W(7-OMe)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2
299	Ac-[Pen]-N-T-[W(7-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2
300	Ac-[Pen]-N-T-[W(7-OMe)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2
314	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ala)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
315	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(IVA)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
316	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(cyclohexanoic)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
317	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(octanoic)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
318	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(C(O)CH_2Ph)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;

SEQ ID NO:	Sequence
319	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(trifluoropropionic)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
320	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
321	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(bAla)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
322	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Aib)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
324	-Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2;
325	-Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
328	Ac-[Pen]-A-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
329	Ac-[Pen]-G-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
330	Ac-[Pen]-[Lys(Ac)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
331	Ac-[Pen]-[Cit]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
332	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
333	Ac-[Pen]-P-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
334	Ac-[Pen]-S-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
335	Ac-[Pen]-[Dab(Ac)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
336	Ac-[Pen]-R-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;

SEQ ID NO:	Sequence
337	Ac-[Pen]-[hLeu]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
338	Ac-[Pen]-[(D)Asn]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2;
349	Ac-[Pen]-N-T-[W(6-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2;
351	Ac-[Pen]-N-T-[W(2-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2;
352	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-S-[(D)Lys]-NH_2;
353	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(2-Me)]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2;
355	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ala)]-N-[(D)Leu]-NH_2;
362	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(PEG3-OMe)]-N-[(D)Leu]-NH_2; or
363	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(PEG11-OMe)]-N-[(D)Leu]-NH_2

5. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II):

X4-X5-X6-X7-X8-X9-X10-X11 (II)

wherein

X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);

X5 is Cit, Glu, Gly, Leu, Ile, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gln, Asp, or Cys; and

~~X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, alpha-MeThr, alpha-MeSer, or Val.~~

~~6. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 or X9 is Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen; and the bond between X4 and X9 is a disulfide bond.~~

~~7. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 is (D)Pen, or Pen; or X4 is Pen(sulfoxide).~~

~~8. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 is Pen.~~

~~9. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-8, wherein X9 is Cys, (D)Cys, or alpha-MeCys.~~

~~10. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-8, wherein X9 is Pen or (D)Pen.~~

~~11. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-8, wherein X9 is Pen.~~

~~12. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 is Pen and X9 is Pen, and the bond is a disulfide bond.~~

~~13. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 or X9 is Abu; and the bond between X4 and X9 is a thioether bond.~~

~~14. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IIa) (IIb), or (IIc):~~

~~Pen-X5-X6-X7-X8-Pen-X10-X11 (IIa),~~

~~Abu-X5-X6-X7-X8-Cys-X10-X11 (IIb), or~~

~~Abu-X5-X6-X7-X8-Pen-X10-X11 (IIc),~~

~~wherein X5-X8 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.~~

~~15. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-14, wherein X5 is Asn, Gln, or Glu.~~

~~16. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-14, wherein X5 is Asn, or Gln.~~

~~17. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-14, wherein X5 is Asn.~~

~~18. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IIIa), (IIIb), (IIIc), or (IIId):~~

~~Pen-Asn-X6-X7-X8-Pen-X10-X11 (IIIa),~~

~~Pen-Gln-X6-X7-X8-Pen-X10-X11 (IIIb),~~

~~Abu-Asn-X6-X7-X8-Cys-X10-X11 (IIIc), or~~

~~Abu-Gln-X6-X7-X8-Pen-X10-X11 (IIId),~~

~~wherein X6-X8 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.~~

~~19. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-18, wherein X6 is Thr.~~

~~20. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IVa), (IVb), (IVc), or (IVd):~~

~~Pen-Asn-Thr-X7-X8-Pen-X10-X11 (IVa),~~

~~Pen-Gln-Thr-X7-X8-Pen-X10-X11 (IVb),~~

~~Abu-Asn-Thr-X7-X8-Cys-X10-X11 (IVc), or~~

~~Abu-Gln-Thr-X7-X8-Pen-X10-X11 (IVd),~~

~~wherein X7-X8 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.~~

~~21. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-20, wherein X8 is Gln, alpha-Me-Lys, alpha-MeLys(Ac), or Glu.~~

~~22. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-20, wherein X8 is Gln.~~

~~23. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Va), (Vb), (Vc), or (Vd):~~

~~Pen-Asn-Thr-X7-Gln-Pen-X10-X11 (Va),~~

~~Pen-Gln-Thr-X7-Gln-Pen-X10-X11 (Vb),~~

~~Abu-Asn-Thr-X7-Gln-Cys-X10-X11 (Vc), or~~

~~Abu-Gln-Thr-X7-Gln-Pen-X10-X11 (Vd)~~

~~wherein X7 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.~~

~~24. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Ve), (Vf), (Vg), or (Vh):~~

~~Pen-Asn-Thr-X7-Lys(Ac)-Pen-X10-X11 (Ve),~~

~~Pen-Gln-Thr-X7-Lys(Ac)-Pen-X10-X11 (Vf),~~

~~Abu-Asn-Thr-X7-Lys(Ac)-Cys-X10-X11 (Vg), or~~

~~Abu-Gln-Thr-X7-Lys(Ac)-Pen-X10-X11 (Vh)~~

~~wherein X7 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.~~

~~25. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-24, wherein X10 is Phe, Phe[4-(2-aminoethoxy)], Phe[4-(2-acetylaminoethoxy)], or Phe(4-$CONH_2$).~~

~~26. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-24, wherein X10 is Phe[4-(2-aminoethoxy)], or Phe[4-(2-acetylaminoethoxy)].~~

~~27. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula(VIa), (VIb), (VIc), or (VId):~~

~~Pen-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11 (VIa),~~

~~Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11 (VIb),~~

~~Abu-Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11 (VIc), or~~

~~Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11 (VId)~~

~~wherein X7 and X11 are as described in claim 1; [F(4-2ae)] is Phe[4-(2-aminoethoxy)].~~

~~28. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIe), (VIf), (VIg), or (VIh):~~

~~Pen-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11 (VIe),~~

~~Pen-Gln-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11 (VIf),~~

~~Abu-Asn-Thr-X7-Lys(Ac)-Cys-[F(4-2ae)]-X11 (VIg), or~~

~~Abu-Gln-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11 (VIh)~~

~~wherein X7 and X11 are as described in claim 1; [F(4-2ae)] is Phe[4-(2-aminoethoxy)].~~

~~29. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIIa), (VIIb), or (VIIc):~~

~~Pen-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIa),~~

~~Abu-Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIb), or~~

~~Abu-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIc)~~

~~wherein X7 and X11-X15 are as described in claim 1.~~

~~30. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIId), (VIIe), or (VIIf) or comprises a sequence of Formula (VIId), (VIIe), or (VIIf):~~

~~Pen-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIId),~~

~~Abu-Asn-Thr-X7-Lys(Ac)-Cys-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIe), or~~

~~Abu-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIf)~~

~~wherein X7 and X11-X15 are as described in claim 1.~~

~~31. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-30, wherein X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, Ala, cyclohexylAla, Lys, or Aib.~~

~~32. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-30, wherein X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, or alpha-MeLeu.~~

~~33. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-30, wherein X12 is alpha-MeLeu.~~

~~34. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-31, wherein X13 is Glu, Gln, Lys(Ac), or Lys.~~

~~35. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-31, wherein X13 is Gln, Lys(Ac), or Lys.~~

~~36. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-31, wherein X13 is Lys(Ac), or Lys.~~

~~37. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-31, wherein X13 is Lys(Ac).~~

~~38. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIIIa), (VIIIb) or (VIIIc):~~

~~Pen-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-aMeLeu-K(Ac)-X14-X15 (VIIIa),~~

~~Abu-Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-aMeLeu-K(Ac)-X14-X15 (VIIIb), or~~

~~Abu-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-aMeLeu-K(Ac)-X14-X15 (VIIIc)~~

~~wherein X7, X11, X14, and X15 are as described in claim 1.~~

~~39. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIIId), (VIIIe) or (VIIIf) or comprises a sequence of Formula (VIIId), (VIIIe) or (VIIIf):~~

~~Pen-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11-[alpha-MeLys]-K(Ac)-X14-X15 (VIIId),~~

~~Abu-Asn-Thr-X7-Lys(Ac)-Cys-[F(4-2ae)]-X11-[alpha-MeLys]-K(Ac)-X14-X15 (VIIIe), or~~

~~Abu-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11-[alpha-MeLys]-K(Ac)-X14-X15 (VIIIf)~~

~~wherein X7, X11, X14, and X15 are as described in claim 1.~~

~~40. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-39, wherein X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and X11 is as described in claim 1.~~

~~41. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and X7 is as described in claim 1.~~

~~42. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal.~~

~~43. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is 2-Nal, or 1-Nal.~~

~~44. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is 2-Nal.~~

~~45. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is 1-Nal.~~

~~46. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IVa):~~

~~Pen-Asn-Thr-X7-X8-Pen-X10-X11 (IVa),~~

~~wherein X8, X10, and X11 are as in claim 1, and X7 is Trp substituted with alkyl, and the substitution is at 1-, 2, or 7-position.~~

2. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein X7 is Trp substituted with alkyl, and the substitution is at a 1-, 2-, or 7-position

~~47.~~3. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of claim ~~46~~2, wherein X7 is Trp substituted with 1-Me, 2-Me, or 7-Me.

~~48.~~4. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-47~~ claim 2, wherein X8 is Gln, alpha-Me-Lys, alpha-MeLys(Ac), or Glu.

~~49.~~5. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-47~~ claim 2, wherein X8 is Gln.

~~50.~~6. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof ~~of any one~~ of ~~claims 46-47~~ claim 2, wherein X8 is Gln, Cit, alpha-MeLys, alpha-MeLeu, Aib, or Lys(AC).~~Q, Cit, a-MeLys, a-MeLeu, Aib, Lys(Ac), Lys(Gly), or Lys(Aib).~~

~~51.~~7. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-47~~ claim 2, wherein X8 is Lys(Ac).

~~52.~~8. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-51~~ claim 2, wherein X10 is Phe, Phe[4-(2-aminoethoxy)], Phe[4-(2-acetylaminoethoxy)], or Phe(4-$CONH_2$).

~~53.~~9. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-51~~ claim 2, wherein X10 is Phe[4-(2-aminoethoxy)], or Phe[4-(2-acetylaminoethoxy)].

~~54.~~10. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-53~~ claim 2, wherein X11 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy.

~~55.~~11. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-53~~ claim 2, wherein X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal.

~~56.~~12. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-53~~ claim 2, wherein X11 is 2-Nal, or 1-Nal.

~~57.~~13. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of ~~any one of claims 46-53~~ claim 2, wherein X11 is 2-Nal.

~~58. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-57, wherein the peptide inhibitor comprises the structure of Formula (Z):~~

~~R^1-X-R^2 (Z)~~

~~or a pharmaceutically acceptable salt or solvate thereof, wherein~~

~~R^1 is hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-C1-C6alkyl, or a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing;~~

~~X is the amino acid sequence of Formula (I), any of Formula (II)-(XII), or an amino acid sequence set forth in Table E3; and~~

~~R^2 is OH or NH_2.~~

~~59. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 58, wherein X is the amino acid sequence of Formula (II').~~

~~60. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 58, wherein the peptide comprises X-R^2, and X is the amino acid sequence of Formula (II'), and R^2 is OH or NH_2.~~

~~61. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 58, wherein the peptide comprises an amino acid sequence of Formula (II"):~~

~~X7-X8-X9-X10-X11-X12-X13-X14-X15-R^2 (II").~~

~~62. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-61, wherein the peptide inhibitor comprises the structure of Formula (Z):~~

~~R^1-X-R^2 (Z)~~

~~or a pharmaceutically acceptable salt or solvate thereof, wherein~~

~~R^1 is a bond, hydrogen, Ac, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-C1-C6alkyl, or a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing;~~

~~X is the amino acid sequence of Formula (II'); and~~

~~R^2 is OH or NH_2;~~

~~or wherein the peptide inhibitor of Formula (Z) is a peptide having an amino acid sequence set forth in Table E3 or a pharmaceutically acceptable salt or solvate thereof.~~

~~63. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 58-62, wherein R^1 is H or C1-C20 alkanoyl.~~

~~64. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 58-62, wherein R^1 is H or Ac.~~

~~65.~~14. The peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof ~~any one of claims 58-62~~ of claim 1, wherein R^1 is Ac.

~~66.~~15. The peptide inhibitor or pharmaceutically acceptable salt thereof ~~-~~of claim 1, wherein the peptide inhibitor ~~comprises or~~ is:
Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 201);
Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 227);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 242);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 245);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Cit]-NH_2 (SEQ ID NO: 249);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2 (SEQ ID NO: 252);
Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 267);
Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 284); or
Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 285).~~:~~
~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2; (SEQ ID NO: 320); or~~
~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Aib)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2; (SEQ ID NO: 322);~~
~~and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via an Abu-C thioether bond;~~

~~or a pharmaceutically acceptable salt or solvate thereof.~~

~~67. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 202);~~

~~Ac-[(D)Arg]-Abu-Q-T-[W(7-Me)]-Q-C-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH_2 (SEQ ID NO: 203);~~

~~Ac-Abu-Q-T-[W(7-Me)]-Q-C-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH_2 (SEQ ID NO: 204);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-G-[bA]-NH_2 (SEQ ID NO: 205);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-A-[bA]-NH_2 (SEQ ID NO: 207);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-L-[bA]-NH_2 (SEQ ID NO: 208);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Ala]-[bA]-NH_2 (SEQ ID NO: 209);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-H-[bA]-NH_2 (SEQ ID NO: 214);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-T-[bA]-NH_2 (SEQ ID NO: 217);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-S-[bA]-NH_2 (SEQ ID NO: 221);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Ser]-[bA]-NH_2 (SEQ ID NO: 222);~~

~~Ac-[Pen]-NT-[W(4-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 231);~~

~~Ac-[Pen]-NT-[W(1-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 232);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[a-MeLys]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 234);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[a-MeLeu]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 235);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Aib]-N-[bA]-NH_2 (SEQ ID NO: 236);~~

~~Ac-[Pen]-Q-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 237);~~

~~Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 238);~~

~~Ac-[Pen]-[Lys(Ac)]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 239);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-L-NH_2 (SEQ ID NO: 244);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[bA]-[bA]-NH_2 (SEQ ID NO: 268);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-L-[bA]-NH_2 (SEQ ID NO: 269);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[bA]-[bA]-NH_2 (SEQ ID NO: 270);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-S-[bA]-NH_2 (SEQ ID NO: 271);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-H-[bA]-NH_2 (SEQ ID NO: 272);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-[bA]-[bA]-NH_2 (SEQ ID NO: 273);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Cit]-[bA]-[bA]-NH_2 (SEQ ID NO: 279);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-N-[bA]-NH_2 (SEQ ID NO: 282);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[W(1-Me)]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 283);~~

~~Ac-[Pen]-N-T-[W(7-i-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 286);~~

~~Ac-[Pen]-N-T-[W(7-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 288);~~

~~Ac-[Pen]-N-T-[W(7-OMe)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2 (SEQ ID NO: 297);~~

~~Ac-[Pen]-N-T-[W(7-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2 (SEQ ID NO: 299);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ala)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2; (SEQ ID NO: 314);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(IVA)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2; (SEQ ID NO: 315);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(cyclohexanoic)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2; (SEQ ID NO: 316);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(bAla)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2; (SEQ ID NO: 321); or~~


~~Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2; (SEQ ID NO: 325);~~

~~and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;~~

~~or a pharmaceutically acceptable salt or solvate thereof.~~


~~68.~~16. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor ~~comprises or~~ is:

~~Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (Seq. ID. No. 238)~~




,

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (Seq. ID. ~~No~~NO.: 242)




,

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. ~~No~~NO.: 245)




,

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Cit]-NH_2 (Seq. ID. ~~No~~NO~~.~~: 249)




,

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2 (Seq. ID. ~~No~~NO~~.~~: 252)




,

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (Seq. ID. ~~No~~NO~~.~~: 267)




,

Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. ~~No~~NO~~.~~: 284)




, or

Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. ~~No~~NO~~.~~: 285)




~~,~~.

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 320)~~




~~,~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Aib)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 322)~~



~~, or~~


~~Ac-[Pen]-[Dab(Ac)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 335)~~



and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond;

or a pharmaceutically acceptable salt or solvate thereof.


69. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is: Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (Seq. ID. No. 238)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.


70.17. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises or is:

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (Seq. ID. NoNO.: 242)




~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof~~.

~~71.~~18. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor ~~comprises or~~ is:
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. ~~No.~~NO: 245)




~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof~~.

~~72.~~19. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor ~~comprises or~~ is:
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Cit]-NH_2 (Seq. ID. ~~No.~~NO: 249)




~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof~~.

~~73.~~20. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor ~~comprises or~~ is Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2 (Seq. ID. ~~No~~NO.: 252)



~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof~~.


~~74.~~21. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor ~~comprises or~~ is: Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (Seq. ID. ~~No~~NO.: 267)



~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof~~.

~~75.~~22. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor ~~comprises or~~ is:


Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. ~~No~~NO~~.~~: 284)



~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof~~.


~~76.~~23. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor ~~comprises or~~ is:

Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. ~~No~~NO~~.~~: 285)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

77. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is: Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 320)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

78. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is: Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Aib)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 322)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

79. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is: Ac-[Pen]-[Dab(Ac)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 335)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

80. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is: Ac-[(D)Arg]-Abu-Q-T-[W(5-F)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH_2
(SEQ ID NO: 364).

81. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (I):

X7-X8-X9-X10-X11 (I)

wherein

X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X8 is Gln, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp;

X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);

X10 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy; and

X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

and

provided that

i) at least one of X7 and X11 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

ii) X7 is other than 5-F substituted Trp;

iii) when X7 is unsubstituted Trp, or Trp substituted with 1-Me, 5-OH or 6-Cl; then X9 is other than Cys; and

iv) the compound is other than

Ac-[Pen]-NT-[W(5-Cl)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 1);

Ac-[Pen]-NT-[W(6-Cl)-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 2);

Ac-[Pen]-NT-[W(6-F)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 3);

~~Ac-[Pen]-NT-[W(4-OMe)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 4);~~

~~Ac-[Pen]-NT-[W(6-Me)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 5);~~

~~Ac-[Pen]-NT-[W(7-Me)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 6);~~

~~Ac-[Pen]-NT-[W(5-F)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 7);~~

~~Ac-[Pen]-NT-[W(7-F)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 8);~~

~~Ac-[Pen]-NT-[W(5-OMe)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 9);~~

~~Ac-[Pen]-NT-[W(5-OH)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 10);~~

~~Ac-[Pen]-NT-[W(5-Br)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 11);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(5-Cl)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 12);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(6-Cl)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 13);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(6-F)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 14);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(4-OMe)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 15);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(6-Me)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 16);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(7-Me)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 17);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(5-F)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 18);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(7-F)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 19);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(5-OMe)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 20);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(5-OH)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 21);~~

~~Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(5-Br)-[α-MeLeu]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 22);~~

~~Ac-[(D)Arg]-[Abu]-QT-[W(7-Me)]-QC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-ENN-NH_2 (SEQ ID NO: 27);~~

~~Ac-[Abu]-QT-[W(7-Me)]-QC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-ENN-NH_2 (SEQ ID NO: 28);~~

~~Ac-[(D)Arg]-[Abu]-QT-[W(7-Me)]-QC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 29); or~~

~~Ac-[Abu]-QT-[W(7-Me)]-QC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-NN-NH_2 (SEQ ID NO: 30);~~

~~wherein Pen-Pen form a disulfide bond, or Abu-Cys form a thioether bond;~~

~~and~~

~~wherein the peptide inhibitor inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.~~

~~82. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 81, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II'):~~

~~X7-X8-X9-X10-X11-X12-X13-X14-X15 (II')~~

~~and wherein~~

~~X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;~~

~~X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or~~

~~X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;~~

X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);

X15 is Asn, Leu, Aib, (D)Leu, beta-Ala, Cit, Gln, Asp, alpha-MeGln, alpha-MeAsn, Lys(Ac), (D)Lys, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or absent.

83. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II'):

X7-X8-X9-X10-X11-X12-X13-X14-X15 (II')

wherein

X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X8 is Gln, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp;

X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);

X10 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, 2-acetylaminoethoxy, 2-Nal, His, His_3Bom, or His_Bzl;

X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, Aib, Achc, Spiral-Pip, DiethylGly, Acbc, or a-MeOrn;

X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Lys, or Gly; or X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;

X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac),

Dab(Ac), Dap(Ac), homo-Lys(Ac), Lys(Ac), (D)Leu, Pro, (D)Pro, (D)Phe, (D)His, Ile, (D)Thr, Gly, N-MeAla, Sarc, or aMeLeu;

X15 Leu, (D)Leu, beta-Ala, Cit, (D)Lys-Arg, NMeArg, bhPhe, His, Val, (D)Val, (D)Lys, Pro, (D)Pro, Ile, (D)Arg, (D)Phe, (D)Tyr, Ser, (D)Ser, Thr, (D)Thr, N-MeAla, Y, a-MePhe, Sarc, Gly, Ala, (D)Tyr, (D)2-Nal, (D)Asn, or absent;

and

provided that at least one of X7 and X11 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; or the peptide inhibitor is

SEQ ID NO: 264	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-NH_2

or

SEQ ID NO: 340	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[bA]-NH_2

.

84. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 83, wherein the peptide inhibitor comprises or is any one of the following or a pharmaceutically acceptable salt or solvate thereof:

SEQ ID NO:	**Sequence***
210	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Leu]-[bA]-NH_2
211	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-P-[bA]-NH_2
212	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Pro]-[bA]-NH_2
213	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Phe]-[bA]-NH_2
215	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)His]-[bA]-NH_2

SEQ ID NO:	Sequence*
216	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-I-[bA]-NH_2
218	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Thr]-[bA]-NH_2
219	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-G-P-[bA]-NH_2
220	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-G-[(D)Pro]-[bA]-NH_2
223	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[N-MeAla]-[bA]-NH_2
224	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[Sarc]-[bA]-NH_2
225	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[a-MeLeu]-[bA]-NH_2
243	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-R-NH_2
246	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[NMeArg]-NH_2
247	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bhPhe]-NH_2
248	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-NH_2
250	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-V-NH_2
251	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Val]-NH_2
252	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2
253	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-P-NH_2

SEQ ID NO:	Sequence*
254	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Pro]-NH_2
255	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-I-NH_2
256	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Arg]-NH_2
257	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Phe]-NH_2
258	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Phe]-NH_2
259	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-NH_2
260	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-S-NH_2
261	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Ser]-NH_2
262	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-NT-NH_2
263	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Thr]-NH_2
265	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[N-MeAla]-NH_2
266	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-Y-NH_2
274	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Achc]-[Lys(Ac)]-N-[bA]-NH_2
275	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Spiral_Pip]-[Lys(Ac)]-N-[bA]-NH_2
276	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[DiethylGly]-[Lys(Ac)]-N-[bA]-NH_2

SEQ ID NO:	Sequence*
277	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acbc]-[Lys(Ac)]-N-[bA]-NH_2
278	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeOrn]-[Lys(Ac)]-N-[bA]-NH_2
289	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[2-Nal]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
290	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-H-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
291	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[His_3Bom]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
292	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[His_Bzl]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
293	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[His_Bzl]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2
323	Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH_2;
326	Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-NH_2;
327	Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[a-MePhe]-NH_2;
339	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Sarc]-NH_2;
341	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-G-NH_2;
342	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-A-NH_2;
343	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-R-NH_2;

SEQ ID NO:	Sequence*
344	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Lys]-NH_2;
345	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Arg]-NH_2;
346	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Phe]-NH_2;
347	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Tyr]-NH_2;
348	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)2-Nal]-NH_2; or
354	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[(D)Asn]-NH_2;
356	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(IVA)]-N-[(D)Leu]-NH_2;
357	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(cyclohexanoic)]-N-[(D)Leu]-NH_2;
358	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(octanoic)]-N-[(D)Leu]-NH_2;
359	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(C(O)CH2Ph)]-N-[(D)Leu]-NH_2;
360	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(trifluoropropionic)]-N-[(D)Leu]-NH_2; or
361	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(valeric)]-N-[(D)Leu]-NH_2

~~or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;~~

~~and~~

~~wherein the peptide inhibitor or pharmaceutically acceptable salt of solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.~~

~~85. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH_2; (SEQ ID NO: 323); or~~

~~and wherein the peptide inhibitor is cyclized via a Abu-C thioether bond;~~

~~or a pharmaceutically acceptable salt or solvate thereof.~~

~~86. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-NH_2 (SEQ ID NO: 248);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Val]-NH_2 (SEQ ID NO: 251);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Arg]-NH_2 (SEQ ID NO: 256);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Phe]-NH_2 (SEQ ID NO: 258);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-NH_2 (SEQ ID NO: 259);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-S-NH_2 (SEQ ID NO: 260);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Ser]-NH_2 (SEQ ID NO: 261);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Thr]-NH_2 (SEQ ID NO: 263);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-NH_2 (SEQ ID NO: 264);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[N-MeAla]-NH_2 (SEQ ID NO: 265);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Achc]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 274);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[DiethylGly]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 276);~~

~~Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acbc]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 277); or~~

~~Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeOrn]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 278);~~

~~and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;~~

~~or a pharmaceutically acceptable salt or solvate thereof.~~

~~87. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:~~

~~Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)His]-[bA]-NH_2 (SEQ ID NO: 215);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-R-NH_2 (SEQ ID NO: 243);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[NMeArg]-NH_2 (SEQ ID NO: 246);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bhPhe]-NH_2 (SEQ ID NO: 247);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-V-NH_2 (SEQ ID NO: 250);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-P-NH_2 (SEQ ID NO: 253);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Pro]-NH_2 (SEQ ID NO: 254);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-I-NH_2 (SEQ ID NO: 255);~~

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Phe]-NH_2 (SEQ ID NO: 257);~~

~~or~~

~~Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH_2; (SEQ ID NO: 323);~~

~~and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;~~

~~or a pharmaceutically acceptable salt or solvate thereof.~~


~~88. The peptide inhibitor of claim 83, wherein the peptide inhibitor comprises or is: Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[2-Nal]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 289); or~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-H-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 290);~~

~~and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;~~


~~or a pharmaceutically acceptable salt or solvate thereof.~~

~~89. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-NH_2 (Seq. ID. No. 248)~~




~~,~~


~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-NH_2 (Seq. ID. No. 259)~~



~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Ser]-NH_2 (Seq. ID. No. 261)~~




~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Thr]-NH_2 (Seq. ID. No. 263)~~




,

~~Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-NH_2 (Seq. ID. No. 264)~~



,


~~Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[bA]-NH_2 (SEQ ID NO: 340)~~



,

or

Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Lys]-NH_2 (SEQ ID NO: 344)




;

and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond;

or a pharmaceutically acceptable salt or solvate thereof.


90. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:

Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-NH_2 (Seq. ID. No. 248)




~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.~~

~~91. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-NH_2 (Seq. ID. No. 259)~~




~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.~~

~~92. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Ser]-NH_2 (Seq. ID. No. 261)~~




~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.~~

~~93. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Thr]-NH_2 (Seq. ID. No. 263)~~



~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.~~


~~94. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-NH_2 (Seq. ID. No. 264)~~



~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.~~


~~95. The peptide inhibitor of claim 83, wherein the peptide inhibitor comprises or is:~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-H-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. No. 290)~~



~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.~~


~~96. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[bA]-NH_2 (SEQ ID NO: 340)~~



~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.~~

~~97. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:~~

~~Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Lys]-NH_2 (SEQ ID NO: 344)~~



~~wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond;~~
~~or a pharmaceutically acceptable salt or solvate thereof.~~

~~98. A polynucleotide comprising a sequence encoding the peptide inhibitor of any one of claims 1-97.~~

~~99. A vector comprising the polynucleotide of claim 98.~~

~~100.~~24. A pharmaceutical composition comprising the peptide inhibitor or pharmaceutically acceptable salt ~~or solvate~~ thereof of claim 1 ~~any one of claims 1-97~~, and a pharmaceutically acceptable carrier, excipient, or diluent.

~~101. The pharmaceutical composition of claim 100, further comprising an enteric coating.~~

~~102. The pharmaceutical composition of claim 101, wherein the enteric coating protects and releases the pharmaceutical composition within a subject's lower gastrointestinal system.~~

~~103. A method for treating an Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (*nontropical Sprue*), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, or graft versus host disease in a subject, comprising providing to the subject an effective amount of the peptide inhibitor or peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-98, or the pharmaceutical composition of any one of claims 101-103.~~

~~104. The method of claim 103, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof or the pharmaceutical composition is provided to the subject by an oral, parenteral, intravenous, peritoneal, intradermal, subcutaneous, intramuscular, intrathecal, inhalation, vaporization, nebulization, sublingual, buccal, parenteral, rectal, intraocular, inhalation, topically, vaginal, or topical route of administration.~~

~~105. The method of claim 103 for treating an Inflammatory Bowel Disease (IBD), wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof or the pharmaceutical composition is provided to the subject orally.~~

~~106. The method of claim 105, wherein the IBD is ulcerative colitis.~~

~~107. The method of claim 105, wherein the IBD is Crohn's disease.~~


~~108. The method of claim 103 for treating psoriasis, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof or the pharmaceutical composition is~~

~~provided to the subject orally, topically, parenterally, intravenously, subcutaneously, peritonealy, or intravenously.~~


25. The pharmaceutical composition of claim 24, wherein the peptide inhibitor is:
Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 201);
Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 227);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 242);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 245);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Cit]-NH_2 (SEQ ID NO: 249);
Ac-[Pen]-N--T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2 (SEQ ID NO: 252);
Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 267);
Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 284); or
Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. No. 285).

26. The pharmaceutical composition of claim 24, wherein the peptide inhibitor is:


Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 242)




Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 245)



Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Cit]-NH_2 (SEQ ID NO: 249)




Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH_2 (SEQ ID NO: 252)




,

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH_2 (SEQ ID NO: 267)




Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (SEQ ID NO: 284)



, or

Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH_2 (Seq. ID. No. 285)



.

27. Use of a peptide inhibitor or a pharmaceutically acceptable salt thereof according to any of claims 1-23, or a pharmaceutical composition according to any of claims 24-26, in the preparation of a medicament for the treatment of a disease or disorder involving autoimmune inflammation.

28. Use of a peptide inhibitor or a pharmaceutically acceptable salt thereof according to any of claims 16-23, or a pharmaceutical composition according to claim 26, in the manufacture of a medicament for the treatment of a disease or disorder involving autoimmune inflammation.

29. The use of claim 27 or claim 28, wherein the disease or disorder is selected from the group consisting of: multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel diseases (IBDs), juvenile IBD, adolescent IBD, Crohn's disease, sarcoidosis, Systemic Lupus Erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis (PsA), psoriasis (PsO), atopic dermatitis, acne ectopica, ulcerative colitis, Crohn's disease (CD), Celiac disease (nontropical Sprue), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich Syndrome, pouchitis, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, viral-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, and graft versus host disease.

30. The use of claim 29, wherein the disease or disorder is seleced from the group consisting of: Inflammatory Bowel Disease (IBD), Ulcerative colitis (UC), Crohn’s Disease (CD), psoriasis (PsO), and psoriatic arthritis (PsA).

31. The use of claim 30, wherein the disease or disorder is Inflammatory Bowel Diseases (IBDs).

32. The use of claim 30, wherein the disease or disorder is Ulcerative colitis (UC).

33. The use of claim 30, wherein the disease or disorder is Crohn’s Disease (CD).

34. The use of claim 30, wherein the disease or disorder is psoriasis (PsO).

35. The use of claim 33, wherein the psoriasis is plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, Palmo-Plantar Pustulosis, psoriasis vulgaris, or erythrodermic psoriasis.

36. The use of claim 30, wherein the disease or disorder is psoriatic arthritis (PsA).

37. A peptide inhibitor or a pharmaceutically acceptable salt thereof according to any of claims 1-23, or a pharmaceutical composition according to any of claims 24-26, for use in the treatment of a disease or disorder involving autoimmune inflammation.

38. A peptide inhibitor or a pharmaceutically acceptable salt thereof according to any of claims 16-23, or a pharmaceutical composition according to claim 26, for use in the treatment of a disease or disorder involving autoimmune inflammation.